BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Inflammatory disorder
,
Breast
,
Pharmacogenetics
,
Cisplatin
,
rs6983267
,
SNCA
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
NM_023116
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Heart ventricle
Pituitary gland
Nipple cross-section
Heart atrium
Thalamus lateral nuclei
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Loading...
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Loading...
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Loading...
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
A novel calcium channel Cavβ2 splice variant with unique properties predominates in the retina.
A Preclinical Study on Brugada Syndrome with a CACNB2 Variant Using Human Cardiomyocytes from Induce…
Autism-associated mutations in the CaVβ2 calcium-channel subunit increase Ba2+-currents and lead to …
A Post-GWAS Functional Analysis Confirming Effects of Three BTA13 Genes CACNB2, SLC39A12, and ZEB1 o…
Active Zone Trafficking of CaV2/UNC-2 Channels Is Independent of β/CCB-1 and α2δ/UNC-36 Subunits.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
There were no clinical trials for NM_023116
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ